טוען...
Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
[Image: see text] Inhibition of Bcr-Abl kinase activity by imatinib for the treatment of chronic myeloid leukemia (CML) currently serves as the paradigm for targeting dominant oncogenes with small molecules. We recently reported the discovery of GNF-2 (1) and GNF-5 (2) as selective non-ATP competiti...
שמור ב:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Chemical Society
2010
|
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2951064/ https://ncbi.nlm.nih.gov/pubmed/20828158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/jm100555f |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|